Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

v3.10.0.1
License, Clinical Trial and Sponsored Research Agreements (Tables)
 6 Months Ended
Jun. 30, 2018
License Agreement Disclosure [Abstract]  
Research and Development Arrangement, Contract to Perform for Others [Table Text Block]
For the three and six months ended June 30, 2018 and 2017, the Company recorded the following expense in research and development for licenses acquired:
 
 
 
For the three months ended June 30,
 
 
For the six months ended June 30,
 
($ in thousands)
 
2018
 
 
2017
 
 
2018
 
 
2017
 
City of Hope
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manufacturing
 
$
-
 
 
$
-
 
 
$
75
 
 
$
-
 
IL13Rα2
 
 
-
 
 
 
-
 
 
 
-
 
 
 
250
 
IV/ICV
 
 
-
 
 
 
-
 
 
 
-
 
 
 
125
 
PSCA
 
 
-
 
 
 
300
 
 
 
-
 
 
 
300
 
HER2
 
 
-
 
 
 
600
 
 
 
-
 
 
 
600
 
CS1
 
 
-
 
 
 
600
 
 
 
-
 
 
 
600
 
UCLA
 
 
-
 
 
 
-
 
 
 
-
 
 
 
200
 
Total
 
$
-
 
 
$
1,500
 
 
$
75
 
 
$
2,075
 
 
For the three and six months ended June 30, 2018 and 2017, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:
 
 
 
For the three months ended June 30,
 
 
For the six months ended June 30,
 
($ in thousands)
 
2018
 
 
2017
 
 
2018
 
 
2017
 
City of Hope
 
$
500
 
 
$
500
 
 
$
1,000
 
 
$
1,000
 
City of Hope - CD123
 
 
114
 
 
 
575
 
 
 
264
 
 
 
595
 
City of Hope - IL13Rα2
 
 
143
 
 
 
1,001
 
 
 
503
 
 
 
1,010
 
City of Hope - Manufacturing
 
 
115
 
 
 
-
 
 
 
229
 
 
 
-
 
Fred Hutch - CD20
 
 
418
 
 
 
-
 
 
 
684
 
 
 
-
 
Total
 
$
1,290
 
 
$
2,076
 
 
$
2,680
 
 
$
2,605